- Rifamycin sodium salt
-
- $1.00
-
2026-07-05
- CAS:14897-39-3
- Min. Order: 1g
- Purity: 0.99
- Supply Ability: 20 tons
- Rifamycin Sodium
-
-
2026-07-03
- CAS:14897-39-3
- Min. Order: 1KG
- Purity: 98%min
- Supply Ability: 500kg
- Rifamycin S
-
- $5.70
-
2026-05-28
- CAS:14897-39-3
- Min. Order: 10kg
- Purity: 99%
- Supply Ability: 10000kg
|
| | Rifamycin Sodium Basic information |
| | Rifamycin Sodium Chemical Properties |
| Melting point | >215°C (dec.) | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | ethanol: soluble50mg/mL | | form | powder | | color | Dark Red | | Water Solubility | Soluble in water, alcohol and dimethyl sulfoxide. | | Merck | 13,8302 | | InChIKey | DJAAUWJRMPPGDA-HSBICLRHNA-N | | SMILES | [Na+].CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)cc([O-])c4c3C2=O |
| Safety Statements | 22-24/25 | | WGK Germany | 3 | | RTECS | KD1922500 | | F | 8-10-23 | | Storage Class | 11 - Combustible Solids |
| | Rifamycin Sodium Usage And Synthesis |
| Chemical Properties | Dark Red Solid | | Uses | Rifamycin SV Sodium (Rifaximin EP Impurity C) is a semi-synthetic antibiotic derived from Rifamycin S. (1) Antibacterial (2). Potency >900 units (dry basis). | | Uses | Semi-synthetic antibiotic derived from Rifamycin S. Antibacterial. Potency >900 units (dry basis). | | Biological Activity | Rifamycin SV inhibits selective (E. coli, B. subtilis) bacterial DNA-dependent RNA polymerase by binding to the polymerase β-subunit, a mechanism similar to rifabutin. It acts as a selective cytochrome P450 3A4 inducer. It is active against Gram-positive bacteria and is moderately active against Gram-negative organisms. | | in vivo | Rifamycin (5 mg/day; s.c.; 3 days a week) sodium is effective in mice infected with M. tuberculosis, significantly reducing the number of viable bacteria in the body[4].
Rifamycin (12.5-25 mg/kg; peritoneal lavage) sodium can improve the survival rate of rats with experimental intraperitoneal infection and significantly reduce the number of intraperitoneal bacteria and adhesion formation[6].
Rifamycin (5-40 mg/kg; esophageal gavage; once a day, 5 days a week; 4 weeks) sodium shortens oral treatment duration in a mouse model of Mycobacterium ulcerans disease[8].
Rifamycin (0.1 mL; intraaural administration; twice daily; 10 days) sodium does not cause hearing loss in adult or weanling rats[9].
Rifamycin (1 mg i.v. bolus followed by 4 mg i.v. infusion; 70 min) sodium interferes with three major steps of Bile acid metabolism in rats with intravenous Sodium cholate (HY-N0324A) infusion, resulting in a significant decrease in bile acid uptake and excretion[10].
Rifamycin (10-160 mg/kg; s.c.; single dose) sodium is approximately 11 times less effective than Metronidazole (HY-B0318) in a mouse Bacteroides fragilis thigh infection model[11].
| Animal Model: | Male Wistar rats (weight 200-250 g), cecal ligation puncture (CLP)-induced intra-abdominal infection model[6] | | Dosage: | 25 mg/kg, 12.5 mg/kg | | Administration: | Peritoneal lavage | | Result: | Improved survival from 50% in the control group to 91.7% in the 25 mg/kg group and 100% in the 12.5 mg/kg group.
Significantly reduced adhesion formation.
Showed a greater reduction in bacterial counts in peritoneal fluid (25 mg/kg).
|
|
| | Rifamycin Sodium Preparation Products And Raw materials |
|